METTL3 and urinary bladder cancer: Zhao et al. (2019) identified METTL3 as a driver gene in a bladder cancer cohort using the integrated statistical model-based method called driver MAPS. However, in the subsequent experimental verification of this finding, the researchers found that METTL3 knockdown significantly increased cell proliferation. Furthermore, METTL3 somatic mutations could promote cancer cell growth by interrupting RNA methylation. Therefore, they believe that METTL3 acts as a tumor suppressor for bladder cancer (Zhao et al., 2019).